Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
207 results about "Intestinal inflammation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Functional probiotic fermented fruit and vegetable powder preparation method
The present invention provides a functional probiotic fermented fruit and vegetable powder preparation method, a functional probiotic fermented fruit and vegetable powder product is prepared by low temperature spray drying method, and the advantages are in that: (1) vitamin and dietary fiber and other nutritional components in raw fruits and vegetables can be effectively saved, after fermentation, free amino acid and organic acid contents are increased greatly, the product not only has good nutrition, color and flavor, and good water solubility, is free of any flavor and pigments, and belongs to pure natural green food; (2) the activity of probiotics in the product can be effectively saved (live bacteria number is 106cfu / g-1010cfu / g), a large number of active probiotics have the special beneficial functions of regulating the human body intestinal environment, preventing intestinal inflammation and cancer, improving constipation and other functions, and common fruit and vegetable powder does not have the special beneficial functions; (3) the preparation method has the advantages of low processing equipment investment, high efficiency and low energy consumption, the cost can be reduced by more than 80%, the production is easy to enlarge, and the preparation method is suitable for industrial continuous production, and can truly meet the needs of ordinary consumers.
Owner:熊涛 +1
Lactobacillus plantarum ZS2058 and application thereof
InactiveCN105106246AImprove diarrheaImprove blood in stoolDigestive systemUnknown materialsStool occult bloodGenetics
The invention relates to lactobacillus plantarum ZS2058 and application thereof. The lactobacillus plantarum ZS2058 and the application have the advantages that colitis symptoms of diarrhea, stool occult blood, hematochezia and the like of mice can be effectively improved by the lactobacillus plantarum ZS2058, increase of disease activity indexes (DAI) can be suppressed, change of the lengths of colons of the mice can be improved, the activity of myeloperoxidase (MPO) can be obviously reduced, and the lactobacillus plantarum ZS2058 can be used for preparing medicine for preventing and treating intestinal inflammation or producing food beneficial to the intestinal health.
Owner:JIANGNAN UNIV
Bamboo powder feed and method for feeding rabbit
The invention discloses a bamboo powder feed and a method for feeding a rabbit, relates to development and application of bamboo in cultivation industry and also relates to a feed, in particular to a feed and the feeding method of the rabbit. The bamboo powder feed comprises bamboo poles and / or bamboo powder, wherein the bamboo powder is made by smashing and drying bamboo leaves and is used in a mixed way according to a proportion of 10-18 percent of the total quantity of the feed, namely, 25 percent of corn starch, 19.6 percent of wheat bran, 18.5 percent of bean pulp, 0.4 percent of silkworm chrysalis, 12 percent of alfalfa meal, 15 percent of bamboo powder and 9.5 percent of micro-element additive. The bamboo powder feed is suitable for growth demand of herbivore and can partially or completely substitute the traditional fiber raw material such as alfalfa and the like, on the basis of ensuring feed nutrients, herbage raw materials consumption is reduced, grazing and land resources are saved, common diseases such as respiratory tract, intestinal inflammation and the like of the rabbit can be effectively prevented, rabbit growth is facilitated, and growth rate of the rabbit can be accurately improved; and meanwhile, bamboo fiber is more resistant to digestion, so that the total consumption of the feed is relatively reduced, and cultivation cost is saved.
Owner:TONGLIANG ZHUSHAN RABBIT IND
Health-care medicinal liquor with function for tonifying kidney and preparation method thereof
InactiveCN101411807ANo side effectsFull of nutritionHeavy metal active ingredientsAnthropod material medical ingredientsCervical spondylopathyIntestinal inflammation
The invention discloses health-care medicinal liquor with the function of invigorating kidney and a preparation method thereof which belong to the technical field of traditional Chinese medicine. The health-care medicinal liquor is prepared from the following raw materials in weight portion: distilled spirit, and Chinese herbal medicines of aweto, ginseng, fructus schizandrae, medlar, actinolite, male silk moth, astragalus root, herba epimedii, herba cistanches, semen alli tuberosi, yam and tuckahoe. The total effective rate of the health-care medicinal liquor for renal deficiency, renal hypofunction patients, nephropathy, prostatitis, rheumatoid arthritis, cervical spondylopathy and lumbar intervertebral disc protrusion can reach over 90 percent. The health-care medicinal liquor also has auxiliary treatment and health-care function on gastritis, gastric cold, intestinal inflammation, irregular menses, adnexitis, hyperplasia of mammary glands, hypopiesis and arrhythmia. The health-care medicinal liquor has a simple concoction process, available material source, no risk in production, transportation and storage, and wide market prospect.
Owner:刘境
Healthcare agent for pet puppies
InactiveCN105230987AMake up for nutritional imbalancesIncrease nutritionAnimal feeding stuffBiotechnologyVitamin C
The invention discloses a healthcare agent for pet puppies. The healthcare agent for pet puppies comprises the following ingredients in parts by mass: 5-10 parts of egg micro-capsule powder, 5-15 parts of hydrolyzed wheat protein, 0.5-1.5 parts of vitamin A, 3-10 parts of glucose, 2-5 parts of chicken liver powder, 0.3-1 part of vitamin D3, 15-25 parts of puffed oat flour, 15-25 parts of puffed corn flour, 5-8 parts of vitamin C and 30-50 parts of skimmed milk powder. The healthcare agent for pet puppies of the invention is capable of supplementing nutrients required puppy growth and development, increasing pet appetite, reinforcing body immunity, preventing and treating intestinal inflammation, improving pet physique as well as improving hair quality. The healthcare agent for pet puppies is obvious in effect, safe and free of toxic and side effects.
Owner:山东贝瑞康生物科技有限公司
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
InactiveUS7175847B1Prevent rejectionAvoid immune responseImmunoglobulins against bacteriaImmunoglobulins against cytokines/lymphokines/interferonsAntigenCD80
Owner:BIOGEN INC
Methods for treating inflammation by disrupting MCH-mediated signaling
InactiveUS20080124319A1Inhibitory activityAvoid damageAntipyreticAnalgesicsIntestinal inflammationMCH receptors
Disclosed herein are methods for treating an inflammatory condition in a patient comprising administering an agent that inhibits the signaling activity of MCH, thereby inhibiting the inflammatory response in the tissue, and in a mammal comprising administering to the mammal an effective amount of an agent that inhibits MCH activity, MCH binding to an MCH receptor or the signaling activity of an MCH receptor that mediates intestinal inflammation.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.
Owner:GW PHARMA LTD
Application of Tibet rhodiola crenulata extract in preparing medicament for resisting intestinal inflammation
The invention provides an application of Tibet rhodiola crenulata extract in preparing a medicament for resisting intestinal inflammation. The rhodiola crenulata extract is obtained by adopting a water extraction method, and is subjected to a drosophila intestinal inflammatory injury repairing experiment. Results prove that the rhodiola crenulata extract has excellent anti-inflammation and anti-oxidation activities, and can be used for preparing medicaments for resisting intestinal inflammation.
Owner:NORTHEAST FORESTRY UNIVERSITY +1
Gap Junction-Enhancing Agents for Treatment of Necrotizing Enterocolitis and Inflammatory Bowel Disease
ActiveUS20130345154A1Reduce riskImprove mobilityBiocideAntipyreticEnterocolitisIntestinal inflammation
The present invention relates to methods of reducing the risk of occurrence of, and / or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.
Owner:UNIVERSITY OF PITTSBURGH
Probiotic compositions for improving metabolism and immunity
ActiveUS20180125900A1Increase fat massEnhanced energy extractionUnknown materialsBacteroidesImmunologic disorders
The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera Ileibacterium and Dubosiella, including their species I. valens (I. valens) and Dubosiella newyorkensis (D. newy), respectively, and closely related OTUs within the family Erysipelotrichaceae that resemble either Ileibacterium spp. or Dubosiella spp. with 90% 16S rRNA sequence identity, for modulating weight and intestinal inflammation and immunity (including modulating intestinal immune gene expression such as, e.g., modulating expression of RORγT, IL-17A, IL-17F, RegIIIγ, Relmβ, and Defβ), as well as for treatment and diagnosis of (i) obesity and related conditions such as metabolic syndrome and diabetes mellitus; (ii) allergic and autoimmune diseases, and (iii) gastrointestinal disorders (such as, e.g., inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and celiac disease).
Owner:NEW YORK UNIV
Use of modified polysaccharide rich in mannose in preparing medicine for preventing the colitis cancer
InactiveCN101306012APrevent cancerRelieve inflammationOrganic active ingredientsDigestive systemGut immunityUlcerative colitis
The invention relates to the application of a mannose-enriched polysaccharide to drug preparation, in particular to the application of a mannose-enriched modified polysaccharide to the preparation of drugs for preventing colonitis from cancerization. Aiming to make up the blank of the drugs for preventing the inflammatory bowel diseases and especially the ulcerative colitis from cancerization, the application provides the technical proposal that the mannose-enriched modified polysaccharide is applied to the drugs for preventing the colonitis from cancerization, and the modified polysaccharide contains a modified natural gum or a modified plant polysaccharide. The application has the characteristics that a mannose receptor (MR) is taken as a target; the mannose-enriched polysaccharide is separated and extracted from a medicinal plant, and mannosidase is adopted for hydrolyzation; mannose residues are exposed, and regulate gut immunity and relieve the intestinal inflammation after being combined with the MR on the surface of immunological cells, thereby preventing the inflammatory bowel diseases and especially the ulcerative colitis from cancerization. After the mannose-enriched modified polysaccharide is used on a big mouse suffering from the ulcerative colitis, the cancerization inhibitory rate of the ulcerative colitis can reach 93 percent.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Agents for improving inflammatory bowel disease
InactiveUS20090202517A1Seizure suppressionIncrease the number ofCompound screeningOrganic active ingredientsLarge intestineChondroitin Sulfate Proteoglycans
The present inventors discovered for the first time that intestinal inflammation could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, inflammation in the large intestine can be suppressed by using siRNA to suppress the expression of versican, which is one of the chondroitin sulfate proteoglycans. Compounds used as siRNA, such as nucleic acids, can be used as effective agents for suppressing intestinal inflammation. Furthermore, the above finding also suggests that such intestinal inflammation-suppressing agents can be found by screening for compounds that suppress the production or accumulation of chondroitin sulfate proteoglycans.
Owner:STELIC INST OF REGENERATIVE MEDICINE
Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
InactiveUS20140286908A1Prevent thermal degradationIncrease temperatureBiocideOrganic active ingredientsTolerabilityIntestinal inflammation
The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and / or in the prevention and / or treatment of intestinal inflammation, such as necrotizing enterocolis, and / or in the recovery after intestinal injury and / or surgery. This composition is particularly adapted for use in infants, notably preterm infants.
Owner:SOC DES PROD NESTLE SA
Piglet creep feed capable of improving intestinal health and preparation method of piglet creep feed
InactiveCN105595005AHigh nutritional valueReduce weaning stressFood processingAnimal feeding stuffPropionateAnimal science
Owner:NANCHANG AONONG BIOLOGICAL SCI & TECH
Glucan polymer, polymer micelle and medicine carrier system
The invention relates to a glucan polymer, a polymer micelle and a medicine carrier system. The glucan polymer is prepared from glucan, 4-(hydroxymethyl)benzeneboronic acid pinacol ester and polyol fatty acid through reaction, wherein the glucan and the polyol fatty acid provide hydrophilic and hydrophobic units, so that the polymer can automatically form the micelle; the polymer formed by the glucan, the 4-(hydroxymethyl)benzeneboronic acid pinacol ester and the polyol fatty acid through chemical reaction is sensitive to hydrogen peroxide; the response can be fast generated on hydrogen peroxide in an environment of ROS high expression diseases (such as myocardial ischemial injury, atherosclerosis, intestinal inflammation and tumor); the micelle disassembly is caused, so that the medicinemolecules are fast released.
Owner:THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Plant lactobacillus composition and its application in strengthening intestinal immunobarrier
The present invention relates to a kind of composition containing plant lactobacillus LP-Onlly strain and its application in strengthening intestinal immunobarrier. The composition of the present invention can intervene the homing of intestinal lymphocyte, control the number of intestinal tract secretive IgA and intestinal lymphocyte, lower the endotoxin level, improve intestinal tract immunobarrier and prevent damage of intestinal tract immunobarrier caused by hunger, malnutrition, infection, etc, and prevent and treat intestinal inflammation, infectious diseases and immune disorder diseases.
Owner:SHANGHAI JIAODA ONLLY CO LTD
Compositions And Methods Related To An Intestinal Inflammation And Uses Therefor
InactiveUS20080194456A1Reducing pathogen infectionHigh expressionBiocidePeptide/protein ingredientsInflammatory Bowel DiseasesIntestinal inflammation
Described herein are screening methods to identify therapeutic compositions for the treatment of an intestinal inflammation, inflammatory bowel disease or pathogen infection, as well as therapeutic methods and compositions useful for ameliorating an intestinal inflammation, inflammatory bowel disease or pathogen infection.
Owner:THE GENERAL HOSPITAL CORP
Naphthalene sulfonamide compound and preparation methods and applications thereof
ActiveCN110256305AReduce inflammatory damageHas anti-inflammatory activityOrganic active ingredientsNervous disorderDiseaseMedicine
The invention discloses a naphthalene sulfonamide compound and preparation methods and applications thereof. The naphthalene sulfonamide compound provided by the invention can interfere with Keap1-Nrf2 binding and activate Nrf2 so as to alleviate inflammatory damage and improve inflammatory microenvironment, has potential anti-inflammatory activity, and can be used for preparing anti-inflammatory medicine for the inflammatory damage of many inflammation-related diseases. The diseases include chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal inflammation, rheumatoid arthritis and the like.
Owner:CHINA PHARM UNIV
Bacteroides vulgaris strain and application thereof in preparation of medicines for treating inflammatory bowel diseases
ActiveCN111269852ALower activity indexProtects against inflammatory bowel diseaseBacteriaAntipyreticBiotechnologyIntestinal inflammation
The invention discloses a bacteroides probiotic strain. The preservation number of the bacterial strain is CGMCC NO.17140, the preservation date is January 7, 2019, the bacterial strain is classifiedand named as bacteroides vulgaris, and the preservation unit is China General Microbiological Culture Collection Center. The bacterial strain is harmless to animals and has a remarkable effect of improving and regulating intestinal inflammation. The invention further discloses application of the bacterial strain in preparation of medicines and health care products for preventing and treating inflammatory bowel diseases.
Owner:ICDC CHINA CDC
Application of antibacterial peptide C-BF in preparation of medicines for preventing and treating weanling stress of piglets
InactiveCN104645314AImprove growth performanceIncrease the height of jejunal villiPeptide/protein ingredientsDigestive systemIntraperitoneal routeIntestinal morphology
The invention discloses an application of an antibacterial peptide C-BF in preparation of medicines for preventing and treating weanling stress of piglets. The intestinal morphology can be improved by the antibacterial peptide C-BF; the villus height can be increased; the intestinal inflammation is relieved; the growth performance of weaned pigs is improved; the diarrhea rate is lowered; and the antibacterial peptide C-BF is dosed through intraperitoneal injection.
Owner:ZHEJIANG UNIV
Application of L-fucose in medicines and health-care products for treating gastrointestinal lesions
InactiveCN106668034AReduce incidenceReduce inflammatory damageOrganic active ingredientsDigestive systemTolerabilityPoor compliance
The invention discloses application of L-fucose in medicines and health-care products for treating gastrointestinal lesions. The L-fucose is used for treating the gastrointestinal lesions, such as inflammatory bowel disease, functional gastrointestinal disorder and irritable bowel syndrome. The medicine is a carbohydrate medicine, since the adverse effect is less, and the tolerance of a patient is good, so that the medicine can be widely applied into clinic. The medicine has the advantages that the L-fucose is used in an early period of the gastrointestinal lesions, the activation of mesenteric lymph node Treg cells is regulated by DC cells, the differentiation potential of colons Th1 and Th17 is inhibited, the generation of bile acid is inhibited by regulating the intestinal flora, the function of inhibiting the contraction and spasm of intestinal muscles is realized by an nNOS path, the intestinal inflammation and weight-losing conditions are improved, and the patient can obtain an obvious long-term prognosis benefit; because of limitations of related existing therapy medicines, namely multiple medicine types, large side effect and poor compliance, a new therapy strategy for treating the patients with the gastrointestinal lesions, such as the inflammatory bowel disease, the functional gastrointestinal disorder and the irritable bowel syndrome, is provided.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
InactiveUS20160096885A1Modulate activityMicrobiological testing/measurementImmunoglobulins against cytokines/lymphokines/interferonsInflammatory Bowel DiseasesFibrosis
Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and / or IL-17 and diagnosing the subject.
Owner:CEDARS SINAI MEDICAL CENT
Application of indolepopionic acid to preparation of drugs for preventing and/or treating tumor radiotherapy side effect
ActiveCN108125950ANo heterogeneityNo serious adverse reactionsOrganic active ingredientsMetabolism disorderLaboratory mouseSide effect
The invention belongs to the technical field of medicine, and relates to application of indolepopionic acid to preparation of drugs for preventing and / or treating tumor radiotherapy side effect. Through research, the fact that indolepopionic acid can obviously improve intestinal injury of mice, caused by gama ray irradiation, is found, the improvement shows that the survival rate of laboratory mice is obviously improved, the weight is risen again, the intestinal inflammation level is obviously reduced, and paradoxical reaction of the laboratory mice does not occur, the fact that indolepopionicacid can be effectively applied to the prevention and / or treatment of tumor radiotherapy side effect is shown, and the indolepopionic acid is low in toxic and side effect, and effective before and after being taken, and has a wide application potential.
Owner:崔明 +4
Application of Tibet saussurea laniceps extract to relieving fruit fly intestinal inflammation
The invention discloses application of a Tibet saussurea laniceps extract to relieving fruit fly intestinal inflammation. The Tibet saussurea laniceps extract is obtained by using a water extraction method; a fruit fly intestinal immunologic function damage model repair test is performed on the Tibet saussurea laniceps extract to discover that the Tibet saussurea laniceps extract has good anti-inflammation activity and antioxidant activity and can be used for preparing anti-inflammation medicaments, particularly anti-intestinal inflammation medicaments.
Owner:NORTHEAST FORESTRY UNIVERSITY +1
Anti-stress preparation for pigs and preparation method thereof
InactiveCN106615815AReach stress disorderReduce stressFood processingAnimal feeding stuffAnti stressIntestinal inflammation
The invention discloses an anti-stress preparation for pigs and a preparation method thereof. The anti-stress preparation comprises, by weight parts, 6-8 parts of costusroot, 6-8 parts of fructus aurantii immaturus, 3-4 parts of curcuma aerugionosa, 6-8 parts of tangerine peel, 4-7 parts of rhubarb, 3-6 parts of astragalus, 1-3 parts of scutellaria baicalensis, 6-10 parts of honeysuckle, 7-12 parts of hawthorn, 10-14 parts of raw malt, 3-6 parts of codonopsis pilosula, 1-5 parts of glucose oxidase, 5-7 parts of mannase, 0.8-1.0 part of 5-amino-levulinic acid and 3-4 parts of taurine. According to the anti-stress preparation for pigs and the preparation method thereof, the formula is comprehensively considered from aspects such as immunity boost, anti-stress, qi circulation and spleen strengthening, digestion promotion, stomach invigorating, reduction of intestinal inflammation reaction and oxidative stress, shortcoming in conventional technologies are overcome, anti-stress action is strengthened while growth is promoted, health conditions of pigs are enhanced obviously, and the death rate is greatly reduced.
Owner:SICHUAN WANGDA FEED
Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel
A method for the differentiation of inflammatory bowel disease (IBD) from irritable bowel disease (IBS) followed by distinguishing ulcerative colitis and Crohn's disease from other gastrointestinal illnesses. This highly differential method first uses the presence of elevated lactoferrin as a marker of intestinal inflammation to differentiate IBD from IBS. Patients suspected of IBD are then analyzed for fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as an indicator of Crohn's disease and fecal anti-neutrophil cytoplasmic antibodies (ANCA) as an indicator of ulcerative colitis. IBD patients are further monitored for intestinal inflammation using fecal lactoferrin to evaluate the effectiveness of medical therapy and to predict relapse. The apparatus comprises either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous lactoferrin, ASCA and ANCA in human feces. The method and apparatus can be used by healthcare providers to identify IBD and distinguish ulcerative colitis from Crohn's disease.
Owner:TECH LAB
Application of galanthamine in prevention and treatment for fish enteritis caused by soybean meal feed
ActiveCN110447787AAvoid residueAvoid environmental securityAntipyreticFood processingDiseaseInformation analysis
The invention discloses application of galanthamine in prevention and treatment for soybean meal-induced enteritis of fishes. According to a neuroregulation theory of intestinal mucosal immunity, in combination with two methods of disease modeling and biological information analysis, it is inferred that the galanthamine is a potential medicine for preventing and treating the soybean meal-induced enteritis; it is proved by an experiment that the galanthamine can activate expression of anti-inflammatory cytokines in intestinal tracts of bred fishes through addition into feed or intramuscular injection in backs, inhibit intestinal inflammations, maintain tight junctions of intestinal epithelium barriers, and inhibit intestinal epithelium apoptosis, therefore the enteritis caused by a soybeanmeal feed is relieved, recovery of growth of the fishes can be achieved, and therefore the galanthamine can be taken as a novel feed additive with an anti-inflammatory effect or an injection with an anti-inflammatory effect for injection operation.
Owner:INST OF AQUATIC LIFE ACAD SINICA
Preparation method of polyphenol-amyloid fiber hydrogel for relieving acute intestinal inflammation of mice
InactiveCN112107536AIncrease loadGood biocompatibilityOrganic active ingredientsAntipyreticPhenolic content in teaIntestinal inflammation
The invention relates to a preparation method of polyphenol-amyloid fiber hydrogel for relieving acute intestinal inflammation of mice. Egg white lysozyme amyloid fiber is prepared through heating under a high-temperature acidic condition, polyphenol is simply added into the amyloid fiber, and reversible hydrogel is formed through self-assembly. By constructing an IBD animal model, the hydrogel isused for gavage treatment of the mice, and the inventor finds that the hydrogel can significantly relieve DSS-induced acute colitis. All the materials used in the invention are food-grade and are safer than medicines for preventing or treating intestinal inflammation, and a new thought is provided for developing tea polyphenol products and medicines having anti-inflammatory activity and improvedbioavailability.
Owner:NANJING AGRICULTURAL UNIVERSITY
Compound poplar flower oral liquor and preparation method
ActiveCN101548996AImprove the immunityImprove gastrointestinal muscleAntibacterial agentsDigestive systemMedicineAtropine sulfate
The present invention provides a compound poplar flower oral liquor. Each 100 ml solution contains medicinal ingredient as follows: ofloxacin 4.0-7.0 g, atropine sulfate 0.03-0.05 g, poplar flower extract liquid 93-96 ml, each 1 ml poplar flowers extract liquid equals to 1.10-1.15 g of poplar flowers raw ingredient. The compound poplar flower oral liquid can prevent and treat diarrhea or intestinal inflammation of the animal efficiently, optimize treating effect. The compound poplar flower oral liquid is added into drinking water for animal in general, each 100 oral liquid is added with 200 jin water, and the patient animal can be cured after taking the oral liquid 2-3 days. The compound poplar flower oral liquid has obvious treating effect and does not relapse after taking.
Owner:HENAN SOAR VETERINARY PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com